Skip to content

CRESCENT BIOPHARMA, INC.: 10-Q filed 2014-07-31

What CRESCENT BIOPHARMA, INC. reported in its quarterly report filed 2014-07-31 (fiscal Q2 2014): 31 published measures, 89 facts as tagged in accession 0001193125-14-289579.

This filing

Form
10-Q (quarterly report)
Filed
2014-07-31
Fiscal period
fiscal Q2 2014
Accession
0001193125-14-289579 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CRESCENT BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-3067,519,596USD
At 2013-12-315,283,474USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-06-303,635,742USD
At 2013-12-312,376,055USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-3063,883,854USD
At 2013-12-312,907,419USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-06-3066,217,242USD
At 2013-12-312,310,603USD
At 2013-06-3010,777,982USD
At 2012-12-3117,372,832USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-307,991,721USD91
2014-01-01 to 2014-06-302,889,870USD181
2013-04-01 to 2013-06-30-3,497,060USD91
2013-01-01 to 2013-06-30-3,037,371USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-06-3095,737USD181
2013-01-01 to 2013-06-3030,492USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-04-01 to 2014-06-3015,027,004USD91
2014-01-01 to 2014-06-3015,027,004USD181
2013-04-01 to 2013-06-3055,074USD91
2013-01-01 to 2013-06-303,862,665USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-06-30-60,385,539USD
At 2013-12-31-63,275,409USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2014-04-01 to 2014-06-3018,807,675shares91
2014-01-01 to 2014-06-3018,020,121shares181
2013-04-01 to 2013-06-30946,363shares91
2013-01-01 to 2013-06-30938,446shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2014-04-01 to 2014-06-3020,238,343shares91
2014-01-01 to 2014-06-3019,472,995shares181
2013-04-01 to 2013-06-30946,363shares91
2013-01-01 to 2013-06-30938,446shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2014-04-01 to 2014-06-300.42USD/shares91
2014-01-01 to 2014-06-300.16USD/shares181
2013-04-01 to 2013-06-30-3.7USD/shares91
2013-01-01 to 2013-06-30-3.24USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2014-04-01 to 2014-06-300.39USD/shares91
2014-01-01 to 2014-06-300.15USD/shares181
2013-04-01 to 2013-06-30-3.7USD/shares91
2013-01-01 to 2013-06-30-3.24USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2014-04-01 to 2014-06-3076,758USD91
2014-01-01 to 2014-06-3076,758USD181
2013-01-01 to 2013-06-300USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-06-30420,640USD
At 2013-12-31399,799USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-06-308,064,216USD91
2014-01-01 to 2014-06-302,957,592USD181
2013-04-01 to 2013-06-30-3,496,956USD91
2013-01-01 to 2013-06-30-3,038,236USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-3067,098,956USD
At 2013-12-314,883,675USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-06-303,596,905USD
At 2013-12-312,279,299USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-06-30472,161USD
At 2013-12-311,144,895USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2014-04-01 to 2014-06-301,605,092USD91
2014-01-01 to 2014-06-302,829,995USD181
2013-04-01 to 2013-06-30668,253USD91
2013-01-01 to 2013-06-301,274,192USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-04-01 to 2014-06-305,357,696USD91
2014-01-01 to 2014-06-309,239,417USD181
2013-04-01 to 2013-06-302,883,777USD91
2013-01-01 to 2013-06-305,626,709USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-3018,893,464shares
At 2013-12-311,426,593shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-06-30124,250,499USD
At 2013-12-3166,150,674USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-06-301,245,595USD
At 2013-12-311,155,710USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-06-30824,955USD
At 2013-12-31755,911USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-06-302,640,591USD
At 2013-12-31685,746USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-06-30881,714USD
At 2013-12-312,573,072USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2014-04-01 to 2014-06-308,068,479USD91
2014-01-01 to 2014-06-302,966,628USD181
2013-04-01 to 2013-06-30-3,497,060USD91
2013-01-01 to 2013-06-30-3,037,371USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2014-04-01 to 2014-06-3038,852USD91
2014-01-01 to 2014-06-3073,472USD181
2013-04-01 to 2013-06-3032,378USD91
2013-01-01 to 2013-06-3064,319USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2014-04-01 to 2014-06-304,263USD91
2014-01-01 to 2014-06-309,036USD181
2013-04-01 to 2013-06-30-104USD91
2013-01-01 to 2013-06-30865USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-01-01 to 2014-06-3057,248,219USD181
2013-01-01 to 2013-06-300USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-06-30-672,734USD181
2013-01-01 to 2013-06-30-215,635USD181

Inspect the source

Entity
CRESCENT BIOPHARMA, INC. / CIK 0001253689
Captured
2026-09-20T07:46:49.806Z
SEC response SHA-256
b4a6cd55809d9037713a6469afddaa482d358690abc0227f51b6714b6bda1dce

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001253689.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))